Preacutionary labelling of cross-reactive foods: The case of rapeseed

Asthma Research and Practice

Alessandro Fiocchi, Lamia Dahdah, Carla Riccardi, Oscar Mazzina and Vincenzo Fierro

Abstract

Food allergic individuals are exposed to unnecessary dietary restrictions due to precautionary food allergy labelling (PFAL). Two forms of PFAL exist: type I identifies the possible presence of allergenic contaminaion in foods (‘may content…’), type II indicates as potentially dangerous ingredients or contaminants that do no belong to official list of food allergens. PFAL type II is based on the fear of cross-reactivity with foods belonging to that list. PFAL type II is less known, but may be tempting for the legal offices of food companies, for clinicians in a ‘defensive medicine’ key, and even for legislators. We identify here a case of PFAL type II, allergy to rapeseed (belonging to the family of Brassicaceae). Increasingly used for their nutritional and nutraceutic value in asthma prevention, rapeseed has been indicated by regulatory authorities in Canada and Europe as potential cross-reactor with mustard. In this review, we provide the elements for a risk assessment of cross-reactivity of rapeseed/mustard allergy in the general population both clinically and from the point of view of the molecular allergy. Three findings emerge:

1. Allergic reactions to rapeseed are exceptional

2. The allergens identified in rapeseed and mustard are similar, but not identical

3. Reactions to rapeseed have never been described in mustard-allergic patients.

On the ground of existing evidence, a precautionary labeling for rapeseed as potentially dangerous for patients allergic to mustard is not justified. In the interest of patients with multiple food allergy, PFAL type II must be avoided.

Download PDF

 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: Top story: @MatthewBowdish: 'Castro: Site of action of targeted therapies for s… https://t.co/M5derssa15, see more https://t.…
2hreplyretweetfavorite
Interasma RT @Aller_MD: “Regeneron (REGN) Reports Approval of DUPIXENT in Japan for Treatment of Atopic Dermatitis” https://t.co/kUdtuobA6v https://t…
2hreplyretweetfavorite
Interasma RT @Aller_MD: Bilastine Newsletter - Discover what´s new in allergy and antihistamines https://t.co/GmJQkUOBIO https://t.co/5pz0xYFzYJ
5hreplyretweetfavorite
Interasma RT @Aller_MD: “Guideline: Experts recommend a single dose of oral steroids for pain relief in acute sore throat” https://t.co/DnEFi1FiCX ht…
5hreplyretweetfavorite
Interasma RT @Aller_MD: Beneficial bacteria on the skin of mice promotes immunity and accelerates wound healing https://t.co/XNFdTCZvsi
5hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma